An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes

Peter Hovind, Steven Lamberts, Wim Hop, Jaap Deinum, Lisc Tarnow, Hans Henrik Parving, Joop A.M.J.L. Janssen*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Objective: Derangements of the GH-IGF-I axis have been associated with microalbuminuria (MA) in type 1 diabetes. The aim of this study was to investigate whether an IGF-I gene promoter polymorphism influenced the development of persistent MA in type 1 diabetes. Design: A prospective follow-up study of a cohort of 277 patients with newly diagnosed type I diabetes consecutively enrolled between September 1979 and August 1984. Methods: Urinary albumin excretion rate over 24 h was measured in each patient at least once a year. Persistent MA was defined as a urinary albumin excretion rate between 30 and 300 mg/24 h. Results: During a median follow-up of 18.0 years (range 1.0-21.5), 79 of 277 patients developed persistent MA. IGF-I gene genotype was available for 216 subjects; in 73% of the subjects, the wild-type genotype of this IGF-I gene polymorphism was present, while 27% had the variant type. At baseline, there were no differences in IGF-I levels and HbA1c, values between subjects with the wild type and subjects with variant type. By Kaplan-Meier analysis, subjects with the variant type of this polymorphism had during follow-up a higher risk of development of MA compared subjects with the wild type (P=0.03). Conclusions: Subjects with the variant type of an IGF-I gene polymorphism had a significantly increased risk of developing MA. This risk was not mediated through changes in circulating IGF-I levels. Our study suggests that in type I diabetes, this IGF-I gene polymorphisin is a risk factor of MA.

    Sider (fra-til)83-90
    Antal sider8
    TidsskriftEuropean Journal of Endocrinology
    Udgave nummer1
    StatusUdgivet - 1 jan. 2007


    Udforsk hvilke forskningsemner 'An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes' indeholder.